

# NEUROVIVE PHARMACEUTICAL

## NeuroSTAT milestone

NeuroVive Pharmaceutical reported an operating loss of cSEK21m for Q2 versus our estimate of cSEK25.5m. In our view, the main event in the quarter was the initiation of part B in the phase I study of KL1333. However, an even more significant value-driving milestone was reached after the end of the quarter with the FDA granting NeuroSTAT fast-track designation. The company will soon initiate a phase IIa trial with NeuroSTAT in patients with moderate-to-severe traumatic brain injury, and as it now has an approved IND, the study can include US centres. We reiterate our fair value of SEK1.55–4.46.

**First subject enrolled in the part B of the phase I study of KL1333.** In our Q1 review, we wrote that the first subject had been enrolled in part A of the study. Part A is a screening phase where subjects are assessed on their eligibility after receiving a single dose as well as the effect of food intake. In July, the company announced that part B had been initiated. Repeated doses are administered to healthy volunteers in part B, which will evaluate healthy volunteers after receiving multiple ascending doses. In our view, it is positive that the study is progressing according to plan. In part C, the company aims to recruit one cohort of eight patients where biomarkers will be evaluated to provide indication of efficacy.


**Approved IND and fast-track designation for NeuroSTAT.** In May, the FDA approved an IND for NeuroSTAT, which means that NeuroVive Pharmaceutical is now eligible to conduct clinical trials with the drug candidate in the US. The approval was based on the company's submission of detailed information regarding pharmacology and toxicology studies, manufacturing information, protocols for proposed clinical studies and information on the qualifications of the clinical investigators. Based on this information, we believe that NeuroSTAT at this point has been proven safe and tolerable. In our view, it is important to establish the safety profile early on in the development process of drugs since about 9% of drug candidates fail in phase III due to safety concerns (Hay et. al, 2014).

**Fair value of SEK1.55–4.46 reiterated.** We continue to base our valuation on a risk-adjusted DCF model to calculate fair values in a bear-case and a bull-case scenario, and reiterate our fair value of SEK1.55–4.46.

Year-end Dec	2015	2016	2017	2018	2019e	2020e	2021e
Revenue (SEKm)	3	0	0	nm	nm	nm	nm
EBITDA adj (SEKm)	-91	-72	-71	-76	-104	-122	-176
EBIT adj (SEKm)	-91	-72	-71	-73	-103	-120	-175
PTP (SEKm)	-91	-72	-71	-73	-103	-120	-175
EPS rep (SEK)	-3.01	-1.67	-1.33	-0.94	-0.62	-0.40	-0.58
Revenue growth (%)	-63.7	-96.1	133.1	nm	nm	nm	nm
EV/Sales adj (x)	65.41	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

NVP versus OMXS30 (12m)



### SUMMARY

Share price (SEK) 1.73  
 Tickers NVP SS, NVP.ST

### CAPITAL STRUCTURE

No. of shares fully dil. (m) 186.0  
 NIBD adj end-2019e (SEKm) 0

Source: Company, DNB Markets (estimates)

Note: Unless otherwise stated, the share prices in this note are the last closing price.

### NEXT EVENT

Q3 2019 report 20/11/2019

### ESTIMATE CHANGES (SEK)

Year-end Dec	2019e	2020e	2021e
Sales (old)	0.00	0.00	0.00
Sales (new)	0.00	0.00	0.00
Change (%)	nm	nm	nm
Change (%)	nm	nm	nm

Source: DNB Markets.

This report has been commissioned and paid for by the company, and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

### ANALYSTS


Patrik Ling

Jon Berggren

Please see the last two pages for important information. This research report was not produced in the US. Analysts employed by non-US affiliates are not registered/qualified research analysts with FINRA in the United States.

# Overview

## Valuation – fair value range per share SEK1.55–4.46



Source: DNB Markets

### Downside risks to our fair value

- We believe the key risks are the outcomes of future efficacy trials. Today, there is very limited clinical data supporting the efficacy of either NeuroSTAT or KL1333.
- Delays in clinical development could have a major share price impact.
- There is a high execution risk in both scenarios since all of the company's assets are in early-stage development.

Source: DNB Markets

### DNB Markets estimates

- For KL1333 we assume a price per patient per year of USD50,000 in the EU and USD100,000 in the US. We assume the same price for a one-time treatment with NeuroSTAT.
- In our bull case, we estimate a peak penetration of 50% in both the US and the EU for MELAS. We estimate off-label usage of 15% and 35%, respectively, in other target indications.
- In our bear case, we estimate a peak penetration of 35% in both the US and the EU for MELAS. We estimate off-label usage of 15% and 35%, respectively, in other target indications.

Source: DNB Markets

### Valuation methodology

- We continue to use a risk-adjusted DCF approach with a bull-case and a bear-case scenario. We discount the value with a WACC of 10% and apply a tax rate of 22% on all future sales.
- In our bull case, we assume an LOA of 15% for KL1333 in MELAS and 5% in other target indications.
- In our bear case, we assume an LOA of 10% for KL1333 in MELAS and 5% in other target indications.


Source: DNB Markets

### Upside risks to our fair value

- Higher sales of KL1333 and/or NeuroSTAT due to a higher price being charged if promising outcomes are shown in pivotal trials.
- Clinical development can accelerate if patients can be recruited to trials faster than anticipated or due to a potential breakthrough designation.
- The company, or one of its assets, is acquired by a large pharma company.

Source: DNB Markets

## Operating cost base bridge 2018–2020e (SEKm)



Source: DNB Markets (forecasts), company (historical data)

26 August 2019

Forecast changes – P&L

(SEKm)	New			Old			Change		
	2019e	2020e	2021e	2019e	2020e	2021e	2019e	2020e	2021e
Revenues	0	0	0	0	0	0	0	0	0
Cost of sales	0	0	1	0	0	1	0	0	0
Gross profit	0	0	1	0	0	1	0	0	0
Operating expenses	-101	-116	-171	-101	-116	-171	0	0	0
EBITDA	-104	-122	-177	-104	-122	-177	0	0	0
EBITDA adj	-104	-122	-176	-104	-122	-176	0	0	0
EBITDA margin (%)	nm	nm	nm	high	high	high	nm	nm	nm
Depreciation	-3	-6	-6	-3	-6	-6	0	0	0
EBITA	-107	-128	-183	-107	-128	-183	0	0	0
Amortisation	0	0	1	0	0	1	0	0	0
EBIT	-103	-120	-175	-103	-120	-175	0	0	0
EBIT adj	-103	-120	-175	-103	-120	-175	0	0	0
Net interest	0	0	0	0	0	0	0	0	0
Net financial items	0	0	0	0	0	0	0	0	0
PBT	-103	-120	-175	-103	-120	-175	0	0	0
Taxes	0	0	0	0	0	0	0	0	0
Net profit	-103	-120	-175	-103	-120	-175	0	0	0
Adjustments to net profit	0	0	1	0	0	1	0	0	0
Net profit adj	-103	-120	-175	-103	-120	-175	0	0	0
<i>Per share data (SEK)</i>									
EPS	-0.62	-0.40	-0.58	-0.62	-0.40	-0.58	0.00	0.00	0.00
<i>Other key metrics (%)</i>									
Revenue growth	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj growth	nm	nm	nm	40.0	17.3	45.6	nm	nm	nm
EPS adj growth	nm	nm	nm	nm	nm	nm	nm	nm	nm
OpFCF	-104	-122	-176	-104	-122	-176	0	0	0
Working capital	0	3	0	0	3	0	0	0	0
NIBD adj	0	0	0	0	0	0	0	0	0

Source: DNB Markets

26 August 2019

## Annual P&amp;L

(SEKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<b>Revenues</b>	1	7	8	3	0	0	0	0	0	0
Cost of sales	0	0	0	0	0	0	0	0	0	1
<b>Gross profit</b>	1	7	8	3	0	0	0	0	0	1
Operating expenses	-18	-29	-53	-93	-71	-70	-71	-101	-116	-171
<b>EBITDA</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-76</b>	<b>-104</b>	<b>-122</b>	<b>-177</b>
Depreciation	0	0	0	-1	-1	-2	-5	-3	-6	-6
<b>EBITA</b>	<b>-17</b>	<b>-22</b>	<b>-46</b>	<b>-93</b>	<b>-73</b>	<b>-73</b>	<b>-81</b>	<b>-107</b>	<b>-128</b>	<b>-183</b>
Amortisation		0	0	0	0	0	0	0	0	1
<b>EBIT</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-73</b>	<b>-103</b>	<b>-120</b>	<b>-175</b>
Net interest	0	0	0	0	0	0	0	0	0	0
Net financial items	0	0	0	0	0	0	0	0	0	0
<b>PBT</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-73</b>	<b>-103</b>	<b>-120</b>	<b>-175</b>
Taxes	0	0	0	0	0	0	0	0	0	0
Effective tax rate (%)	0	0	0	0	0	0	0	0	0	0
<b>Net profit</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-73</b>	<b>-103</b>	<b>-120</b>	<b>-175</b>
Adjustments to net profit	0	0	0	-1	2	0	0	0	0	1
Net profit adj	-16	-22	-46	-92	-70	-71	-73	-103	-120	-175
<i>Per share data (SEK)</i>										
EPS	-0.85	-1.17	-1.53	-3.01	-1.67	-1.33	-0.94	-0.62	-0.40	-0.58
<i>Growth and margins (%)</i>										
Revenue growth	-76.3	422.1	20.2	-63.7	-96.1	133.1	nm	nm	nm	nm
EPS adj growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Gross margin	100.0	100.0	100.0	100.0	100.0	100.0	nm	nm	nm	nm
EBITDA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBITDA adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Depreciation/revenues	-9.6	-2.1	-5.3	-39.7	-950.0	-580.0	nm	nm	nm	nm
EBIT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj margin	-1242.4	-322.3	-543.1	-3024.7	nm	nm	nm	nm	nm	nm
PBT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

26 August 2019

## Adjustments to annual P&amp;L

(SEKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<b>EBITDA</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-76</b>	<b>-104</b>	<b>-122</b>	<b>-177</b>
Other EBITDA adjustments						0	0	0	0	1
EBITDA adj	-16	-22	-45	-91	-72	-71	-76	-104	-122	-176
<b>EBITA</b>	<b>-17</b>	<b>-22</b>	<b>-46</b>	<b>-93</b>	<b>-73</b>	<b>-73</b>	<b>-81</b>	<b>-107</b>	<b>-128</b>	<b>-183</b>
Other EBITA adjustments						0	0	0	0	1
EBITA adj	-17	-22	-46	-93	-73	-73	-81	-107	-128	-182
<b>EBIT</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-73</b>	<b>-103</b>	<b>-120</b>	<b>-175</b>
Other EBIT adjustments		0	0	0	0	0	0	0	0	1
EBIT adj	-16	-22	-45	-91	-72	-71	-73	-103	-120	-175
<b>Net profit</b>	<b>-16</b>	<b>-22</b>	<b>-45</b>	<b>-91</b>	<b>-72</b>	<b>-71</b>	<b>-73</b>	<b>-103</b>	<b>-120</b>	<b>-175</b>
Other EBIT adjustments		0	0	0	0	0	0	0	0	1
Tax adjustments		0	0	0	0	0	0	0	0	0
Other adjustments	0	0	0	-1	2	0				
Net profit adj	-16	-22	-46	-92	-70	-71	-73	-103	-120	-175
<i>Per share data (SEK)</i>										
EPS	-0.85	-1.17	-1.53	-3.01	-1.67	-1.33	-0.94	-0.62	-0.40	-0.58

Source: Company (historical figures), DNB Markets (estimates)

## Cash flow

(SEKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
Net profit	-16	-22	-45	-91	-72	-71	-73	-103	-120	-175
Depreciation and amortisation		0	0	1	1	2	5	3	6	5
Other non-cash adjustments	1	1	0	29	28	11	11	0	0	1
<b>Cash flow from operations (CFO)</b>	<b>-16</b>	<b>-21</b>	<b>-45</b>	<b>-61</b>	<b>-43</b>	<b>-59</b>	<b>-64</b>	<b>-101</b>	<b>-119</b>	<b>-174</b>
<b>Cash flow from investing (CFI)</b>	<b>-10</b>	<b>-80</b>	<b>-201</b>	<b>-23</b>	<b>-25</b>	<b>-15</b>	<b>-4</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Free cash flow (FCF)</b>	<b>-26</b>	<b>-101</b>	<b>-246</b>	<b>-85</b>	<b>-68</b>	<b>-74</b>	<b>-68</b>	<b>-101</b>	<b>-119</b>	<b>-174</b>
<b>Cash flow from financing (CFF)</b>	<b>46</b>	<b>34</b>	<b>77</b>	<b>120</b>	<b>77</b>	<b>9</b>	<b>65</b>	<b>121</b>	<b>119</b>	<b>174</b>
<b>Total cash flow (CFO+CFI+CFF)</b>	<b>24</b>	<b>3</b>	<b>10</b>	<b>47</b>	<b>-3</b>	<b>-64</b>	<b>-3</b>	<b>20</b>	<b>0</b>	<b>0</b>
<i>FCFF calculation</i>										
Free cash flow	-26	-101	-246	-85	-68	-74	-68	-101	-119	-174
Less: net interest	0	0	0	0	0	0	0	0	0	0
<b>Growth (%)</b>										
CFO	-53.7	-32.8	-112.5	-37.6	30.5	-37.5	-8.9	-58.4	-17.6	-46.3
CFI	-43.3	-719.3	-152.8	88.4	-6.8	39.0	74.7	100.0	nm	nm
FCF	-49.6	-294.3	-144.4	65.5	20.2	-9.2	8.4	-49.3	-17.6	-46.3
CFF	11198.0	-27.5	128.0	56.1	-35.3	-88.3	615.9	87.2	-1.8	46.3
FCFF	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

26 August 2019

## Balance sheet

(SEKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<b>Assets</b>	<b>72</b>	<b>89</b>	<b>131</b>	<b>175</b>	<b>181</b>	<b>120</b>	<b>115</b>	<b>152</b>	<b>165</b>	<b>187</b>
Other receivables	1	1	1	2	2	2	1	0	3	0
Cash and cash equivalents	37	40	50	97	93	29	26	46	46	46
<b>Current assets</b>	<b>38</b>	<b>42</b>	<b>51</b>	<b>100</b>	<b>96</b>	<b>33</b>	<b>27</b>	<b>46</b>	<b>49</b>	<b>46</b>
Property, plant and equipment	1	0	0	0	0	0	0	0	0	0
Other intangible assets	33	47	80	75	71	74	73	92	102	127
Non-current financial assets	0	0	0	0	13	13	0	0	0	1
<b>Non-current assets</b>	<b>33</b>	<b>48</b>	<b>80</b>	<b>75</b>	<b>85</b>	<b>88</b>	<b>74</b>	<b>93</b>	<b>103</b>	<b>129</b>
<b>Total assets</b>	<b>72</b>	<b>89</b>	<b>131</b>	<b>175</b>	<b>181</b>	<b>120</b>	<b>115</b>	<b>152</b>	<b>165</b>	<b>187</b>
<b>Equity and liabilities</b>	<b>72</b>	<b>89</b>	<b>131</b>	<b>175</b>	<b>181</b>	<b>120</b>	<b>115</b>	<b>152</b>	<b>165</b>	<b>187</b>
Total equity to the parent	64	75	103	141	155	101	97	132	152	154
Minority interests	-1	-1	5	14	13	5				
<b>Total equity</b>	<b>63</b>	<b>75</b>	<b>108</b>	<b>155</b>	<b>168</b>	<b>106</b>	<b>97</b>	<b>132</b>	<b>152</b>	<b>154</b>
Short-term debt	8	15	23	20	12	14	0	0	0	0
<b>Total current liabilities</b>	<b>8</b>	<b>15</b>	<b>23</b>	<b>20</b>	<b>12</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total non-current liabilities</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total liabilities</b>	<b>8</b>	<b>15</b>	<b>23</b>	<b>20</b>	<b>12</b>	<b>14</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Total equity and liabilities</b>	<b>72</b>	<b>89</b>	<b>131</b>	<b>175</b>	<b>181</b>	<b>120</b>	<b>115</b>	<b>152</b>	<b>165</b>	<b>187</b>

## Key metrics

Source: Company (historical figures), DNB Markets (estimates)

## Valuation ratios

(SEKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<i>Enterprise value</i>										
Share price (SEK)		12.35	36.13	6.80	2.70	2.41	1.25	1.73	1.73	1.73
Number of shares (m)	19.16	21.66	27.79	29.09	49.46	52.33	78.18	165.1	300.0	301.0
Market capitalisation		267	1,004	198	133	126	98	286	519	521
Net interest bearing debt adj	0	0	0	0	0	0	0	0	0	0
EV adj		267	1,004	198	133	126	98	286	519	521
<i>Valuation</i>										
EPS	-0.85	-1.17	-1.53	-3.01	-1.67	-1.33	-0.94	-0.62	-0.40	-0.58
P/E		-10.6	-23.6	-2.3	-1.6	-1.8	-1.3	-2.8	-4.3	-3.0
Average ROE	-34.5%	-32.5%	-49.6%	-69.7%	-44.6%	-51.9%	-72.3%	-89.5%	-84.6%	-114.3%
Earnings yield adj		-9.5%	-4.2%	-44.3%	-61.9%	-55.1%	-75.3%	-36.0%	-23.2%	-33.7%
EV/SALES adj		38.58	120.47	65.41	1129.96	459.05				
EV/EBITDA adj		-12.0	-22.2	-2.2	-1.8	-1.8	-1.3	-2.7	-4.3	-3.0
EV/EBIT adj		-12.0	-22.2	-2.2	-1.8	-1.8	-1.3	-2.8	-4.3	-3.0

Source: Company (historical figures), DNB Markets (estimates)

26 August 2019

**Key accounting ratios**

	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<i>Profitability (%)</i>										
ROA	-31.2	-27.8	-41.1	-59.7	-40.6	-47.3	-62.3	-77.0	-76.3	-100.0
<i>Return on invested capital (%)</i>										
Net PPE/revenues	50.1	6.6	4.1	10.4	232.2	58.9				
Working capital/revenues	55.3	15.8	13.5	78.3	1398.3	570.2				
<i>Cash flow ratios (%)</i>										
FCF/revenues	-1920.7	-1450.8	-2949.8	-2802.8	-57352.5	-26872.4				
FCF/market capitalisation		-37.6	-24.5	-42.8	-50.8	-58.5	-69.4	-35.4	-22.9	-33.4
CFO/revenues	-1188.9	-302.4	-534.6	-2027.5	-36136.4	-21316.4				
CFO/market capitalisation		-7.8	-4.4	-31.0	-32.0	-46.4	-65.4	-35.4	-22.9	-33.4
CFO/current liabilities	-186.6	-144.3	-190.2	-304.3	-343.5	-411.1				
Cash conversion ratio	154.6	450.1	543.2	92.7	93.9	104.0	92.3	98.4	98.7	99.1
OpFCF margin	-1242.4	-322.3	-543.1	-3024.7	-61110.2	-25850.2				
<i>Leverage and solvency (x)</i>										

Source: Company (historical figures), DNB Markets (estimates)

26 August 2019

## Important Information

Company: NeuroVive Pharmaceutical  
 Coverage by Analyst: Patrik Ling  
 Date: 26/08/2019

This report has been prepared by DNB Markets, a division of DNB Bank ASA. DNB Bank ASA is a part of the DNB Group. This report is based on information obtained from public sources that DNB Markets believes to be reliable but which DNB Markets has not independently verified, and DNB Markets makes no guarantee, representation or warranty as to its accuracy or completeness. This report does not, and does not attempt to, contain everything material which there is to be said about the Company. Any opinions expressed herein reflect DNB Markets' judgement at the time the report was prepared and are subject to change without notice. The report is planned updated minimum every quarter.

Any use of non-DNB logos in this report is solely for the purpose of assisting in identifying the relevant issuer. DNB is not affiliated with any such issuer.

This report is for clients only, and not for publication, and has been prepared for information purposes only by DNB Markets, a division of DNB Bank ASA.

This report is the property of DNB Markets. DNB Markets retains all intellectual property rights (including, but not limited to, copyright) relating to the report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of the report contents, either partially or in full, without DNB Markets' explicit and prior written consent. However, buy-side investment firms may use the report when making investment decisions, and may also base investment advice given to clients on the report. Such use is dependent on the buy-side investment firm citing DNB Markets as the source.

### Risk warning – generally high risk

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.

### Conflict of interest

This report has been commissioned and paid for by the company, and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II.

Readers should assume that DNB Markets may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services or other services to the company/companies

Share positions in the company:	Analyst*	Employees**	DNB***	Update
Number of shares	0	0	0	26/08/2019

\*The analyst or any close associates. \*\*Share positions include people involved in the production of credit and equity research, including people that could reasonably be expected to have access to it before distribution.

\*\*\*Share positions as part of DNB Group. Holdings as part of DNB Markets investment services activity are not included.

Recommendation distribution and corporate clients for the last 12 months

	Buy	Hold	Sell	No_rec	Total
Number	138	66	32	13	249
% of total	55%	27%	13%	5%	
DNB Markets client	28%	9%	2%	2%	102



26 August 2019

**Legal statement**

These materials constitute research as defined in section 9-27 (1) of the Norwegian Securities Trading Regulations (Norwegian: verdipapirforskriften), and are not investment advice as defined in section 2-4(1) of the Norwegian securities trading act (Norwegian verdipapirhandelloven). It constitutes an acceptable minor non-monetary benefit as defined in MiFID II.

The analyst hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report, and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report. DNB Markets employees, including research analysts, may receive compensation that is generated by overall firm profitability. Confidentiality rules and internal rules restricting the exchange of information between different parts of DNB Markets/DNB Bank ASA or the DNB Group are in place to prevent employees of DNB Markets who are preparing this report from utilizing or being aware of information available in the DNB Group that may be relevant to the recipients' decisions. DNB Markets and the DNB Group have incorporated internal rules and regulations in order to avoid any potential conflicts of interest.

The Report has been prepared by DNB Markets, a division of DNB Bank ASA, a Norwegian bank organized under the laws of the Kingdom of Norway and under supervision by the Norwegian Financial Supervisory Authority, The Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK, and the Financial Supervisory Authority of Sweden. Details about the extent of our regulation by local authorities outside Norway are available from us on request.

It is issued subject to the General Business Terms for DNB Markets and information about the terms is available at [www.dnb.no](http://www.dnb.no). For requests regarding the General Business Terms of the Singapore Branch of DNB Bank ASA, please contact +65 6212 6144. Information about the DNB Group can be found at [www.dnb.com](http://www.dnb.com). DNB Markets is a member of The Norwegian Securities Dealers Association, which has issued recommendations and market standards for securities companies. The Association's Internet address where the recommendations and market standards can be found is: [www.vpff.no](http://www.vpff.no). This report is not an offer to buy or sell any security or other financial instrument or to participate in any investment strategy. No liability whatsoever is accepted for any direct or indirect (including consequential) loss or expense arising from the use of this report. Distribution of research reports is in certain jurisdictions restricted by law. Persons in possession of this report should seek further guidance regarding such restrictions before distributing this report. The report is not to be distributed or forwarded to private persons in the UK or the US. Please contact DNB Markets at 08940 (+47 915 08940) for further information and inquiries regarding this report, including an overview on all recommendations from DNB Markets over the last 12 Months according to Market Abuse Regulations.

**Additional information for clients in Singapore**

The report has been distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should seek advice from a financial adviser regarding the suitability of any product referred to in the report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. You have received a copy of the report because you have been classified either as an accredited investor, an expert investor or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, in respect of certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 25, 27 and 36 of the FAA. Section 25 of the FAA requires a financial adviser to disclose material information concerning designated investment products which are recommended by the financial adviser to you as the client. Section 27 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 36 of the FAA requires a financial adviser to include, within any circular or written communications in which he makes recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6212 6144 in respect of any matters arising from, or in connection with, the report. The report is intended for and is to be circulated only to persons who are classified as an accredited investor, an expert investor or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6212 6144. We, the DNB group, our associates, officers and/or employees may have interests in any products referred to in the report by acting in various roles including as distributor, holder of principal positions, adviser or lender. We, the DNB group, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, we, the DNB group, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions which are not consistent with the information set out in the report.

**In the United States**

Each research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report; and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report.

The research analyst(s) named on this report are foreign research analysts as defined by FINRA Rule 1050. The only affiliate contributing to this research report is DNB Bank through its DNB Markets division ("DNB Markets/DNB Bank"); the foreign research analysts employed by DNB Markets/DNB Bank are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Markets/DNB Bank as a research provider or the subject company of a DNB Markets/DNB Bank research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc., a separately incorporated subsidiary of DNB Bank that is a U.S. broker-dealer and a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 200 Park Avenue, New York, NY 10166-0396, telephone number +1 212-551-9800.

**In Canada**

The Report has been distributed in reliance on the International Dealer Exemption pursuant to NI 31-103 subsection 8.18(2) and subsection 8.18(4)(b). Please be advised that: 1. DNB Bank ASA (DNB Markets) and DNB Markets, Inc. are not registered as a dealer in the local jurisdiction to make the trade. We provide our services in Canada as an exempt international dealer. 2. The jurisdiction of DNB Bank ASA (DNB Markets) and DNB Markets, Inc.'s head office is Norway. 3. There may be difficulty enforcing legal rights against DNB Bank ASA (DNB Markets) and DNB Markets, Inc. because all or substantially all of their assets may be situated outside of Canada. 4. The name and address of the agent for service of process for DNB Bank ASA (DNB Markets) and DNB Markets, Inc. in the local jurisdiction is:

Alberta: Blake, Cassels & Graydon LLP, 855 - 2nd Street S.W., Suite 3500, Bankers Hall East Tower, Calgary, AB T2P 4J8. British Columbia: Blakes Vancouver Services Inc., 595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC V7X 1L3. Manitoba: Aikins, MacAulay & Thorvaldson LLP, 30th Floor, Commodity Exchange Tower, 360 Main Street, Winnipeg, MB R3C 4G1. New Brunswick: Stewart McKelvey, Suite 1000, Brunswick House, 44 Chipman Hill, PO Box 7289, Station A, Saint John, NB E2L 2A9. Newfoundland and Labrador: Stewart McKelvey, Suite 1100, Cabot Place, 100 New Gower Street, P.O. Box 5038, St. John's, NL A1C 5V3. Nova Scotia: Stewart McKelvey, Purdy's Wharf Tower One, 1959 Upper Water Street, Suite 900, P.O. Box 997, Halifax, NS B3J 2X2. Northwest Territories: Gerald Stang, Suite 201, 5120-49 Street, Yellowknife, NT X1A 1P8. Nunavut: Field LLP, P.O. Box 1779, Building 1088C, Iqaluit, NU X0A 0H0. Ontario: Blakes Extra-Provincial Services Inc., Suite 4000, 199 Bay Street, Toronto, ON M5L 1A9. Prince Edward Island: Stewart McKelvey, 65 Grafton Street, Charlottetown, PE C1A 1K8. Québec: Services Blakes Québec Inc., 600 de Maisonneuve Boulevard Ouest, Suite 2200, Tour KPMG, Montréal, QC H3A 3J2. Saskatchewan: MacPherson, Leslie & Tyerman LLP, 1500 Continental Bank Building, 1874 Scarth Street, Regina, SK S4P 4E9. Yukon: Grant Macdonald, Macdonald & Company, Suite 200, Financial Plaza, 204 Lambert Street, Whitehorse, YK Y1A 3T2.

**In Brazil**

The analyst or any close associates do not hold nor do they have any direct/indirect involvement in the acquisition, sale, or intermediation of the securities discussed herein. Any financial interests, not disclosed above, that the analyst or any close associates holds in the issuer discussed in the report is limited to investment funds that do not

mainly invest in the issuer or industry discussed in the report and the management of which these persons cannot influence.